Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

Solid Tumors Clinical Trial

Official title:

A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02610361
• Other study ID #: BGB-283-AU-001
• Secondary ID: ACTRN12614001176
• Status: Completed
• Phase: Phase 1
• Start date: November 20, 2013
• Est. completion date: October 2017

Study information

• Verified date: September 2019
• Source: BeiGene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 131
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provided written informed consent prior to enrollment.

2. Male or female and at least 18 years of age.

3. A life expectancy of at least 12 weeks.

4. Histologically or cytologically confirmed advanced or metastatic solid tumor for which no effective standard therapy is available.

5. One of B-RAF, N-RAS, or K-RAS mutation positive solid tumor.

6. Eastern Cooperative Oncology Group (ECOG) performance status of = 1.

7. Able to swallow and retain oral medication.

8. Adequate bone marrow, liver, and renal function:

• Hemoglobin > 9 g/dL

• Absolute neutrophil count = 1000/mm^3

• Platelets = 100,000/mm^3

• Total bilirubin =1.5 times the upper limit of normal (ULN)

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN (= 5 x ULN for subjects with known liver metastasis)

• Creatinine clearance = 45 mL/min (calculated by the Cockcroft Gault formula).

9. Female subjects are eligible to enter and participate in the study if they are of:

a) Non childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who

i) Has had a hysterectomy,

ii) Has had a bilateral oophorectomy (ovariectomy),

iii) Has had a bilateral tubal ligation, or

iv) Is post menopausal (total cessation of menses for = 1 year).

b) Childbearing potential, has a negative serum pregnancy test at screening (within 7 days of the first investigational product administration), and uses adequate contraception before study entry and throughout the study until 28 days after the last investigational product administration. Adequate contraception, when used consistently and in accordance with both the product label and the instructions of the physician, are defined as follows:

i) Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.

ii) Any intrauterine device with a documented failure rate of less than 1% per year.

iii) Double barrier contraception defined as condom with spermicidal jelly, foam, suppository, or film; OR diaphragm with spermicide; OR male condom and diaphragm.

10. Subjects with treated brain metastasis are eligible to enter and participate in the study if they are neurologically stable.

Exclusion Criteria:

1. Female subjects who are pregnant or lactating.

2. Subjects receiving cancer therapy (chemotherapy or other systemic anti cancer therapies, immunotherapy, radiation therapy, or surgery) at the time of enrollment.

3. Any major surgery within 28 days prior to enrollment.

4. Any radiotherapy within 14 days prior to enrollment, providing the subject has recovered from all toxicities to NCI-CTCAE = Grade 1.

5. Use of any investigational anti cancer drug within 28 days before the first investigational product administration.

6. Unresolved toxicity > Grade 1 (according to NCI-CTCAE, Version 4.03) from previous anti cancer therapy, unless agreed by the sponsor.

7. History or presence of gastrointestinal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.

8. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug or to any component of BGB-283. (To date there are no known Food and Drug Administration [FDA] approved drugs chemically related to BGB-283).

9. Untreated leptomeningeal or brain metastasis. Subjects with previously treated brain metastasis that are asymptomatic, off steroids for longer than 28 days are permitted.

10. Any unstable, pre-existing major medical condition that in the opinion of the Investigator contra indicates the use of an investigational product, including active infection, known human immunodeficiency virus (HIV) positive subjects, or known Hepatitis B or C.

11. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.

12. As a result of the medical interview, physical examination or screening investigations, the investigator considers the subject unfit for study.

13. Is on medication listed in the protocol or requires any of these medications during treatment with BGB-283.

14. Candidates for curative therapy.

15. Unable or unwilling to comply with the required treatment.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumors

Intervention

Drug:
• BGB-283
In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme. In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital	Adelaide	South Australia
Australia	Box Hill Hospital	Box Hill	Victoria
Australia	Chris O'Brien Lifehouse	Camperdown	New South Wales
Australia	Monash Medical Centre	Clayton	Victoria
Australia	Austin Health	Heidelberg	Victoria
Australia	Cabrini Hospital	Malvern	Victoria
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria
Australia	The Alfred Hospital	Melbourne	Victoria
Australia	Linear Clinical Research Limited	Nedlands	Western Australia
Australia	Royal Melbourne Hospital	Parkville	Victoria
Australia	North Coast Cancer Institute	Port Macquarie	New South Wales
Australia	Prince of Wales Hospital	Randwick	New South Wales
Australia	Tasman Oncology Research Ltd	Southport	Queensland
Australia	Westmead Hospital	Westmead	New South Wales
Australia	The Queen Elizabeth Hospital	Woodville South	South Australia
Australia	Princess Alexandra Hospital	Woolloongabba	Queensland
New Zealand	Christchurch Hospital	Christchurch
New Zealand	Dunedin Public Hospital	Dunedin
New Zealand	Waikato Hospital	Hamilton
New Zealand	Wellington Hospital	Wellington

Sponsors (1)

Lead Sponsor	Collaborator
BeiGene

Countries where clinical trial is conducted

Australia,  New Zealand, 

References & Publications (1)

Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events in phase 1a		From first dose to within 28 days of last dose of BGB-283, within 1 years in average
Primary	Objective response rate based on RECIST Version 1.1 in subjects with selected tumor types in phase 1b		From the first administration of the investigational product to the end of the study treatment, within 1 year in average
Secondary	Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast) in phase 1a		During first 2 weeks
Secondary	Area under the plasma concentration-time curve from time 0 to infinity time in (AUC8) in phase 1a		During first 2 weeks
Secondary	Maximum plasma concentration (Cmax) in phase 1a		During first 2 weeks
Secondary	Time to reach maximum plasma concentration (tmax) in phase 1a		During first 2 weeks
Secondary	Terminal elimination half-life (t1/2) in phase 1a		During first 2 weeks
Secondary	Tumor response in phase 1a		Every 6 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, within 1 year in average
Secondary	Number of participants with adverse events in phase 1b		From first dose to within 28 days of last dose of BGB-283, within 1 year in average
Secondary	Progression-free survival (PFS)		The interval from study treatment initiation until the determination of disease progression or death, within 1 year in average